Financial Data and Key Metrics Changes - In 2024, the company achieved a total revenue growth of 31%, driven by the success of eight commercialized medicines, including EPKINLY and TIVDAK [8][10] - Operating profit grew by 26%, reflecting strong business performance despite significant investments [9][10] - Recurring revenues increased by 35%, representing 91% of total revenue, up from 88% in 2023 [41][43] Business Line Data and Key Metrics Changes - EPKINLY generated $281 million in sales for the year, with $78 million in Q4, primarily from the U.S. and Japan [30][34] - TIVDAK produced $131 million in sales for the year, including $38 million in Q4, driven by strong utilization rates [36] - The company has 12 products or candidates in 30 clinical trials, including seven Phase III trials [11] Market Data and Key Metrics Changes - EPKINLY is positioned as the first and only bi-specific approved for dual indications in the U.S. and Japan, with anticipated approval for additional indications [15][34] - TIVDAK is regarded as the global standard of care in advanced cervical cancer, with expected approvals in new markets [36][38] Company Strategy and Development Direction - The company is focused on accelerating late-stage programs and maximizing the success of commercialized medicines, with significant investments planned for 2025 [7][23] - Strategic investments are being made in high-potential programs like EPKINLY, Rina-S, and Acasunlimab, with a disciplined approach to capital allocation [61][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong execution and disciplined investments that have solidified the company's foundation for sustainable success [7][10] - The company anticipates continued growth in recurring revenues and plans to maintain a focus on high-impact late-stage programs [50][56] Other Important Information - The company plans to repurchase approximately 1.9 million shares, equivalent to around $370 million, reflecting confidence in future growth [63] - The effective tax rate decreased to 14.4% from 22.8% due to the recognition of deferred tax assets [47] Q&A Session Summary Question: Confidence in endometrial cancer opportunity for Rina-S - Management highlighted robust efficacy data expected to be presented publicly, driving excitement for the Phase III commitment [71][72] Question: Competitive landscape for EPKINLY in DLBCL - Management noted recent NCCN inclusion of GemOx with EPKINLY, enhancing its competitive positioning [78] Question: Market dynamics for EPKINLY in Q4 - A one-time accounting adjustment in Europe impacted Q4 numbers, but overall growth trajectory remains strong [87] Question: Peak sales estimate for Acasunlimab - Management explained that the estimate considers the competitive landscape and treatment intervals [84][91] Question: Clinical development plans for Rina-S in other solid tumors - The company is enrolling patients in non-small cell lung cancer and triple-negative breast cancer cohorts, with plans for further updates [140]

Year End Results © Genmab 2025 Period Ended December 31, 2024 Forward looking statement This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (includi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ◻ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ◻ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 1 ...

Exhibit 99.1 GENMAB 2024 ANNUAL REPORT Table of Contents | MANAGEMENT'S REVIEW | | | --- | --- | | Our 2030 Vision | 1 | | Chair's Statement | 3 | | Letter from the CEO | 4 | | 2024 at a Glance | 5 | | Consolidated Key Figures | 8 | | 2025 Outlook | 10 | | Our Strategy | 12 | | Who We Are | 14 | | Business Model | 15 | | Value Chain | 15 | | Research and Development Capabilities | 18 | | Bringing Our Own Innovative Medicines to Patients | 19 | | Antibody Discovery and Development | 21 | | Products and Techn ...

Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investor-relations. Conference CallGenmab will hold a conference call to discuss the full year res ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Genmab A/S Sponsored ADR (GMAB) and Qiagen (QGEN) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes compa ...

Genmab A/S Sponsored ADR (GMAB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.T ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely on traditional forms of analysis on ke ...

Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: GMAB) will hold its 2024 R&D Update and ASH Data Review Meeting today, December 11, 2024 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually in English and can be attended via live webcast. To register for the webcast, click https://genmab-post-ash-2024.open-exchange.net/. An archive of the webcast will be available on Gen ...

Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,355 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 554 shares at DKK 962.00,3,436 shares at DKK 1,025.00,4,942 shares at DKK 1,032.00,305 shares at DKK 1,050.00, and1,118 sha ...